The discovery of dabigatran etexilate for the treatment of venous thrombosis

References

• Raskob GE, Angchaisuksiri P, Blanco AN, et al. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol. 2014;34:2363–2371. doi:10.1161/ATVBAHA.114.304488.
   PubMed Web of Science ®Google Scholar
• Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e419S–e496S. doi:10.1378/chest.11-2301.
   PubMed Web of Science ®Google Scholar
• Wells PS, Anderson DR, Rodger M, et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost. 2000;83:416–420.
   PubMed Web of Science ®Google Scholar
• Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015;12:464–474. doi:10.1038/nrcardio.2015.83.
   PubMed Web of Science ®Google Scholar
• Anderson FA Jr., Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003;107:I9–I16. doi:10.1161/01.CIR.0000078469.07362.E6.
   PubMed Web of Science ®Google Scholar
• Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med. 2001;344:1222–1231. doi:10.1056/NEJM200104193441607.
   PubMed Web of Science ®Google Scholar
• Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med. 2000;160:3415–3420.
   PubMed Web of Science ®Google Scholar
• Lane DA, Philippou H, Huntington JA. Directing thrombin. Blood. 2005;106:2605–2612.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799–808.
   PubMed Web of Science ®Google Scholar
• Büller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003;349:1695–1702. doi:10.1056/NEJMoa035451.
   PubMed Web of Science ®Google Scholar
• Büller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med. 2004;140:867–873.
   PubMed Web of Science ®Google Scholar
• Hirsh J. Reversal of the anticoagulant effects of warfarin by vitamin K1. Chest. 1998;114:1505–1508.
   PubMed Web of Science ®Google Scholar
• Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines. 8th ed. Chest. 2008;133:141S–159S. doi:10.1378/chest.08-0689.
   PubMedGoogle Scholar
• Prins MH, Lensing AW, Bauersachs R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013;11:21. doi:10.1186/1477-9560-11-21.
   PubMedGoogle Scholar
• Raskob G, Büller H, Prins M, et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study–methodological implications for clinical trials. J Thromb Haemost. 2013;11:1287–1294. doi:10.1111/jth.12230.
   PubMed Web of Science ®Google Scholar
• van Ryn J, Goss A, Hauel N, et al. The discovery of dabigatran etexilate. Front Pharmacol. 2013;4:12. doi:10.3389/fphar.2013.00012.
   PubMed Web of Science ®Google Scholar
• Palta S, Saroa R, Palta A. Overview of the coagulation system. Indian J Anaesth. 2014;58:515–523. doi:10.4103/0019-5049.144643.
   PubMedGoogle Scholar
• De Stefano V, Simioni P, Rossi E, et al. The risk of recurrent venous thromboembolism in patients with inherited deficiency of natural anticoagulants antithrombin, protein C and protein S. Haematologica. 2006;91:695–698.
   PubMed Web of Science ®Google Scholar
• Brouwer J-LP, Lijfering WM, Ten Kate MK, et al. High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin. Thromb Haemost. 2009;101:93–99.
   PubMed Web of Science ®Google Scholar
• Taketomi T, Szlam F, Bader SO, et al. Effects of recombinant activated factor VII on thrombin-mediated feedback activation of coagulation. Blood Coagul Fibrinolysis. 2008;19:135–141. doi:10.1097/MBC.0b013e3282f41e6d.
   PubMed Web of Science ®Google Scholar
• Rao AN, Kazzaz NM, Knight JS. Do neutrophil extracellular traps contribute to the heightened risk of thrombosis in inflammatory diseases? World J Cardiol. 2015;7:829–842. doi:10.4330/wjc.v7.i12.829.
   PubMed Web of Science ®Google Scholar
• Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: chest guideline. Chest. 2016;149:315–352. doi:10.1016/j.chest.2015.11.026.
   PubMed Web of Science ®Google Scholar
• Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 1998;114:445S–469S.
   PubMed Web of Science ®Google Scholar
• Hirsh J, Dalen J, Anderson D, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001;119:8S–21S.
   PubMed Web of Science ®Google Scholar
• Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines. 8th ed. Chest. 2008;133:160S–198S. doi:10.1378/chest.08-0670.
   PubMed Web of Science ®Google Scholar
• Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165:1095–1106. doi:10.1001/archinte.165.10.1095.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368:699–708. doi:10.1056/NEJMoa1207541.
   PubMed Web of Science ®Google Scholar
• Brandstetter H, Turk D, Hoeffken HW, et al. Refined 2.3 A X-ray crystal structure of bovine thrombin complexes formed with the benzamidine and arginine-based thrombin inhibitors NAPAP, 4-TAPAP and MQPA. A starting point for improving antithrombotics. J Mol Biol. 1992;226:1085–1099.
   PubMed Web of Science ®Google Scholar
• Hauel NH, Nar H, Priepke H, et al. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem. 2002;45:1757–1766.
   PubMed Web of Science ®Google Scholar
• Bauer KA. New anticoagulants. Hematology Am Soc Hematol Educ Program. 2006;2006:450–456.
   PubMedGoogle Scholar
• Wienen W, Stassen J-M, Priepke H, et al. Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats. Thromb Haemost. 2007;98:333–338.
   PubMed Web of Science ®Google Scholar
• Wienen W, Stassen J-M, Priepke H, et al. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost. 2007;98:155–162.
   PubMed Web of Science ®Google Scholar
• Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis. 2012;23:138–143. doi:10.1097/MBC.0b013e32834f1b0c.
   PubMed Web of Science ®Google Scholar
• Gosselin RC, Dwyre DM, Dager WE. Measuring dabigatran concentrations using a chromogenic ecarin clotting time assay. Ann Pharmacother. 2013;47:1635–1640. doi:10.1177/1060028013509074.
   PubMed Web of Science ®Google Scholar
• Steiner T, Böhm M, Dichgans M, et al. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol. 2013;102:399–412. doi:10.1007/s00392-013-0560-7.
   PubMed Web of Science ®Google Scholar
• Kitchen S, Gray E, Mackie I, et al. Measurement of non-coumarin anticoagulants and their effects on tests of haemostasis: guidance from the British Committee for Standards in Haematology. Br J Haematol. 2014;166:830–841. doi:10.1111/bjh.12975.
   PubMed Web of Science ®Google Scholar
• van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate–a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116–1127. doi:10.1160/TH09-11-0758.
   PubMed Web of Science ®Google Scholar
• Vilahur G, Padro T, Badimon L. Atherosclerosis and thrombosis: insights from large animal models. J Biomed Biotechnol. 2011;2011:1–12. doi:10.1155/2011/907575.
   Google Scholar
• Stangier J, Rathgen K, Stähle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64:292–303. doi:10.1111/j.1365-2125.2007.02899.x.
   PubMed Web of Science ®Google Scholar
• Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36:386–399. doi:10.1124/dmd.107.019083.
   PubMed Web of Science ®Google Scholar
• Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005;45:555–563. doi:10.1177/0091270005274550.
   PubMed Web of Science ®Google Scholar
• Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost. 2009;15(Suppl 1):9S–16S. doi:10.1177/1076029609343004.
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342–2352. doi:10.1056/NEJMoa0906598.
   PubMed Web of Science ®Google Scholar
• Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129:764–772. doi:10.1161/CIRCULATIONAHA.113.004450.
   PubMed Web of Science ®Google Scholar
• Bytzer P, Connolly SJ, Yang S, et al. Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Clin Gastroenterol Hepatol. 2013;11:246–252. doi:10.1016/j.cgh.2012.10.021.
   PubMed Web of Science ®Google Scholar
• Paden H. Ting N, O’Dea D, Management of gastrointestinal symptoms in patients treated with dabigatran etexilate (Pradaxa) [abstract]. Gastroenterology. 2016;150:S445.
   Google Scholar
• Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368:709–718. doi:10.1056/NEJMoa1113697.
   PubMed Web of Science ®Google Scholar
• Clemens A, Fraessdorf M, Friedman J. Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment. Vasc Health Risk Manag. 2013;9:599–615. doi:10.2147/VHRM.S49830.
   PubMedGoogle Scholar
• Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131:157–164. doi:10.1161/CIRCULATIONAHA.114.012061.
   PubMed Web of Science ®Google Scholar
• Stangier J, Rathgen K, Stähle H, et al. Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. Am J Cardiovasc Drugs. 2009;9:59–68.
   PubMed Web of Science ®Google Scholar
• Härtter S, Sennewald R, Schepers C, et al. Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers. Eur J Clin Pharmacol. 2013;69:327–339. doi:10.1007/s00228-012-1304-8.
   PubMed Web of Science ®Google Scholar
• Ring A, Rathgen K, Stangier J, et al. Dabigatran does not prolong the QT interval with supratherapeutic exposure: a thorough QT study in healthy subjects. Clin Drug Investig. 2013;33:333–342. doi:10.1007/s40261-013-0058-0.
   PubMed Web of Science ®Google Scholar
• Härtter S, Sennewald R, Nehmiz G, et al. Oral bioavailability of dabigatran etexilate (Pradaxa(®)) after co-medication with verapamil in healthy subjects. Br J Clin Pharmacol. 2013;75:1053–1062. doi:10.1111/j.1365-2125.2012.04453.x.
   PubMed Web of Science ®Google Scholar
• Härtter S, Koenen-Bergmann M, Sharma A, et al. Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Br J Clin Pharmacol. 2012;74:490–500. doi:10.1111/j.1365-2125.2012.04218.x.
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim International GmbH. Summary of product characteristics: Pradaxa. [cited 2016 Jan 24]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf
   Google Scholar
• Boehringer Ingelheim Pharmaceuticals Inc. Full prescribing information: Pradaxa. [cited 2016 Jan 24]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022512s024lbl.pdf
   Google Scholar
• Eriksson BI, Dahl OE, Büller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost. 2005;3:103–111. doi:10.1111/j.1538-7836.2004.01100.x.
   PubMed Web of Science ®Google Scholar
• Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO study). Am J Cardiol. 2007;100:1419–1426. doi:10.1016/j.amjcard.2007.06.034.
   PubMed Web of Science ®Google Scholar
• Clemens A, Haertter S, Friedman J, et al. Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification. Curr Med Res Opin. 2012;28:195–201. doi:10.1185/03007995.2011.654109.
   PubMed Web of Science ®Google Scholar
• Fiessinger J-N, Huisman MV, Davidson BL, et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA. 2005;293:681–689. doi:10.1001/jama.293.6.681.
   PubMed Web of Science ®Google Scholar
• Büller HR. Edoxaban versus warfarin for venous thromboembolism. N Engl J Med. 2014;370:80–81. doi:10.1056/NEJMc1313883.
   PubMed Web of Science ®Google Scholar
• Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499–2510. doi:10.1056/NEJMoa1007903.
   PubMed Web of Science ®Google Scholar
• Buller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366:1287–1297. doi:10.1056/NEJMoa1113572.
   PubMed Web of Science ®Google Scholar
• Schulman S, Eriksson H, Kakkar A, et al. Influence of age and renal function on efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER™ and RE-COVER™ II [abstract]. Blood. 2014;124(21):Abstract594.
   Google Scholar
• Schulman S, Eriksson H, Goldhaber SZ, et al. Influence of renal function on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood. 2013;122:212. doi:10.1182/blood-2012-12-471029.
   Web of Science ®Google Scholar
• Schulman S, Goldhaber SZ, Kearon C, et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost. 2015;114:150–157. doi:10.1160/TH14-11-0977.
   PubMed Web of Science ®Google Scholar
• Schulman S, Eriksson H, Goldhaber SZ, et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER™ and RE-COVER™ II [abstract]. Circulation. 2014;130:A18594.
   Web of Science ®Google Scholar
• Schulman S, Goldhaber SZ, Kearon C, et al. Dabigatran or warfarin in the treatment of acute venous thromboembolism in antiphospholipid syndrome [abstract]. J Thromb Haemost. 2015;13(Suppl 2):985. doi:10.1111/jth.12813.
   Web of Science ®Google Scholar
• Majeed A, Goldhaber SZ, Kakkar A, et al. Bleeding events with dabigatran or warfarin in patients with venous thromboembolism. Thromb Haemost. 2016;115:291–298. doi:10.1160/TH15-04-0319.
   PubMed Web of Science ®Google Scholar
• Schulman S, Eriksson H, Kakkar A, et al. Net clinical benefit of dabigatran versus warfarin in prevention of recurrent venous thromboembolism: a pooled analysis of RE-COVER® and RE-COVER II™ [abstract]. J Thromb Haemost. 2015;13(Suppl 2):644. doi:10.1111/jth.12813.
   Web of Science ®Google Scholar
• Goldhaber SZ, Eriksson H, Kakkar A, et al. Influence of polypharmacy on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER® and RE-COVER II™ [abstract]. Circulation. 2015;132:A12422.
   Google Scholar
• Konstantinides SV, Torbicki A, Agnelli G, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014;35:3033–3069k. doi:10.1093/eurheartj/ehu152.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. N Engl J Med. 2010;363:1875–1876. doi:10.1056/NEJMc1007378.
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5:2178–2185. doi:10.1111/j.1538-7836.2007.02748.x.
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Huo MH, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost. 2011;105:721–729. doi:10.1160/TH10-10-0679.
   PubMed Web of Science ®Google Scholar
• Majeed A, Hwang H-G, Connolly SJ, et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation. 2013;128:2325–2332. doi:10.1161/CIRCULATIONAHA.113.002332.
   PubMed Web of Science ®Google Scholar
• Glund S, Stangier J, Schmohl M, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet. 2015;386:680–690.
   PubMed Web of Science ®Google Scholar
• van Ryn J, Norris S, Ramael S, et al. Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab: pooled analysis of phase I data [abstract]. American College of Cardiology Scientific Sessions 2016; Chicago, IL. [cited 2016 Mar 23]. Available from: http://www.abstractsonline.com/pp8/#!/3874/presentation/45221
   Google Scholar
• Pollack CV Jr., Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373:511–520.
   PubMed Web of Science ®Google Scholar
• Pollack CV Jr., Reilly PA, Bernstein R, et al. Design and rationale for RE-VERSE AD: a phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost. 2015;114:198–205.
   PubMed Web of Science ®Google Scholar
• Douketis JD, Healey JS, Brueckmann M, et al. Urgent surgery or procedures in patients taking dabigatran or warfarin: analysis of perioperative outcomes from the RE-LY trial. Thromb Res. 2016;139:77–81.
   PubMed Web of Science ®Google Scholar
• Schulman S. Advantages and limitations of the new anticoagulants. J Intern Med. 2014;275:1–11.
   PubMed Web of Science ®Google Scholar
• Lobmeyer MT, Lehr T, Halton JM, et al. Pharmacokinetics and pharmacodynamics of dabigatran etexilate in adolescents: an open-label phase IIa study [abstract]. Circulation. 2014;130:A18482.
   Google Scholar
• Goldhaber SZ, Ageno W, Casella I, et al. A global prospective cohort study of dabigatran for the treatment of venous thromboembolism (RE-COVERY) [abstract]. J Thromb Haemost. 2015;13(Suppl 2):729.
   PubMed Web of Science ®Google Scholar
• Prandoni P, Prins MH, Cohen AT, et al. Use of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboem-bolism in the EINSTEIN DVT and EINSTEIN PE studies. Acad Emerg Med. 2015;22:142–149.
   PubMed Web of Science ®Google Scholar
• Ageno W, Samperiz A, Caballero R, et al. Duration of anticoagulation after venous thromboembolism in real world clinical practice. Thromb Res. 2015;135:666–672.
   PubMed Web of Science ®Google Scholar
• Beyer-Westendorf J, Ebertz F, Forster K, et al. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC registry. Thromb Haemost. 2015;113:1247–1257.
   PubMed Web of Science ®Google Scholar